QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

HALO

QT78Halozyme Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
68.55
-0.02-0.03%
OverviewShort InterestFilings
HALOQT78Halozyme Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
68.55-0.03%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E23.22EPS (ttm)
2.78
Insider Own1.41%
Shs Outstand118.61M
Perf Week-3.08%
Market Cap8.13BForward P/E6.91EPS next Y9.93Insider Trans0.49%Shs Float-Perf Month-0.26%
Enterprise Value9.97BPEG-EPS next Q1.82Inst Own-Short Float-Perf Quarter8.35%
Income350.54MP/S5.39EPS this Y191.71%Inst Trans-Short Ratio-Perf Half Y6.33%
Sales1.51BP/B36.88EPS next Y22.41%ROA13.05%Short Interest-Perf YTD1.86%
Book/sh1.85P/C11.96EPS next 5Y2.35%ROE126.27%52W High82.22 -16.63%Perf Year29.07%
Cash/sh2.69P/FCF12.18EPS past 3/5Y-ROIC23.65%52W Low51.06 34.25%Perf 3Y-
Dividend Est.-EV/EBITDA15.98Sales past 3/5Y28.40% 39.13%Gross Margin76.93%Volatility2.65% 2.09%Perf 5Y-
Dividend TTM-EV/Sales6.61EPS Y/Y TTM34.69%Oper. Margin56.96%ATR (14)2.34Perf 10Y-
Dividend Ex-Date-Quick Ratio2.33Sales Y/Y TTM48.67%Profit Margin23.13%RSI (14)48.43Recom2.50
Dividend Gr. 3/5Y-Current Ratio2.76EPS Q/Q44.14%SMA20-1.17%Beta0.62Target Price88.25
Payout0.00%Debt/Eq9.76Sales Q/Q42.26%SMA501.02%Rel Volume2.15Prev Close68.57
Employees350LT Debt/Eq43.73EarningsAug 04SMA200-0.89%Avg Volume1.70MPrice68.55
IPO DateMar 16, 2004Option/ShortYes / YesEPS/Sales Surpr.3.23% 5.01%Net Debt/EBITDA2.94Volume3,652,897Change-0.03%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-03-26ReiteratedUBSBuy$56 → $90
May-12-26ReiteratedMorgan StanleyOverweight$96 → $93
Apr-29-26ReiteratedH.C. Wainwright$90 → $95
Apr-21-26ReiteratedMorgan StanleyOverweight$94 → $96
Feb-19-26ReiteratedMorgan StanleyOverweight$78 → $94
Feb-19-26ReiteratedWells FargoEqual Weight$58 → $75
Jan-08-26ReiteratedMorgan StanleyOverweight$79 → $75
Dec-04-25ReiteratedUBSBuy$56
Dec-04-25ReiteratedGoldman SachsNeutral$44 → $56
Nov-04-25ReiteratedJMP SecuritiesMarket Outperform$91 → $92
Latest News
Jun-18-26
Jun-18-2612:37PM
2 Profitable Stocks Worth Your Attention and 1 We QuestionYahoo
Jun-15-26
Jun-15-2610:00AM
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029Yahoo
06:14AM
Halozyme Sees Little Royalty Impact From Medicare Drug Pricing Rule, Says CMS Proposal Should Not Hurt ENHANZE PartnershipsBenzinga
Jun-10-26
Jun-10-2603:30PM
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?Yahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,5091,3971,015
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A348305159
Gross Profit1,1611,091856
Selling, General and Administrative Excl. Other209193154
Research and Development938179
Other Operating Expense-2171
Operating Income859816551
Interest Expense191818
Unusual Expense
———
Non-Operating Income (Expense)337331-24
Net Income Before Taxes503467557
Income Taxes155150113
Consolidated Net Income348317444
Net Income From Continuing Operations348317444
Net Income348317444
EPS (Recurring)2.922.643.50
EPS (Basic, Before Extraordinaries)2.922.643.50
EPS (Diluted)2.782.563.43
EBITDA625573657
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio24.6626.29—
Price To Sales Ratio5.365.78—
Gross Margin76.9478.1084.33
Operating Margin56.9358.4154.29
Net Margin23.0622.6943.74
Shares Outstanding118120127
Market Capitalization8,0898,076—
Operating Lease Expense
———
Insider Trading Volume
$72.89$67.45$62.00$56.55$51.11● Close Price0.00M1.61M3.21M4.82M6.43MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Snyder Mark HowardSVP, CHIEF LEGAL OFFICERJun 12 '26Option Exercise0.0010,068052,644Jun 15 12:00 AM
Torley HelenPRESIDENT AND CEOJun 03 '26Sale69.0710,000690,653767,780Jun 03 12:00 AM
Torley HelenPRESIDENT AND CEOJun 03 '26Option Exercise12.0720,000241,400777,780Jun 03 12:00 AM
Torley HelenPRESIDENT AND CEOJun 02 '26Option Exercise12.0740,000482,800787,780Jun 03 12:00 AM
Torley HelenPRESIDENT AND CEOJun 02 '26Sale66.3920,0001,327,745767,780Jun 03 12:00 AM
Torley HelenPRESIDENT AND CEOJun 01 '26Sale67.5820,0001,351,610767,780Jun 03 12:00 AM
Torley HelenPRESIDENT AND CEOJun 01 '26Option Exercise12.0720,000241,40031,923Jun 03 12:00 AM
Connaughton BernadetteDirectorJun 01 '26Sale66.211,625107,59143,669Jun 02 12:00 AM
Torley HelenPRESIDENT AND CEOMay 13 '26Sale69.1910,000691,908767,780May 13 12:00 AM
Torley HelenPRESIDENT AND CEOMay 13 '26Option Exercise12.0720,000241,400777,780May 13 12:00 AM
Torley HelenPRESIDENT AND CEOMay 12 '26Option Exercise12.0740,000482,800787,780May 13 12:00 AM
Torley HelenPRESIDENT AND CEOMay 12 '26Sale71.7520,0001,435,027767,780May 13 12:00 AM
Torley HelenPRESIDENT AND CEOMay 11 '26Sale65.3520,0001,306,939767,780May 13 12:00 AM
Torley HelenPRESIDENT AND CEOMay 11 '26Option Exercise12.0720,000241,40081,923May 13 12:00 AM
Connaughton BernadetteDirectorMay 01 '26Sale63.481,625103,15538,498May 05 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR